After deep science investor Lindy Fishburne co-founded Breakout Labs within the Thiel Foundation in 2011, she co-founded the seed and early stage venture capital firm Breakout Ventures a few years ago. She has accumulated a large number of shares in the process. Among her company’s portfolio companies, Cortexyme is a company designed to treat Alzheimer’s disease; Sustainable materials manufacturer Modern Meadow; and Strateos, the company’s robotic cloud platform is reshaping the completion of laboratory work the way.This weekend, we spoke with Fishburne, and based on what she saw, we were on the brink of this pandemic. We also talked about why her more investment (which once looked like a long shot) suddenly turned into a reliable bet. The chat content below has been briefly edited to ensure length and clarity.
LF: The popularity of vaccines is something we have never seen in the scientific community. Now, we can really extend it to the less sexy parts of logistics. Obviously, this is our biggest challenge. Then, the next question we will face is, what happens when the level of vaccines in the world is very unequal? How do people feel about travel, contact and fairness on these issues.
LF: Yes. The pandemic has greatly eased the importance of investment in science. For the first time, we really saw the full set of what you think as a traditional technology investor. They read the mRNA vaccine coded by Moderna over a weekend, and they began to believe that we can conduct biology and bioengineering research. No longer like manual craftsmanship.
LF: This is where we want to do manual testing. We are not there yet. You may have read and heard about organs on chips and growing organoids, where you can have a small piece of liver, you can test toxicity on , and we are doing more. That is to say, we are not yet ready to take this step from completely using computer simulation technology to humans with ultra-high confidence. The human body is such a complex system that we cannot yet fully model it.I do think you are referring to the democratization of science to some extent and the way that more people can engage in drug discovery and drug development remotely with lower skills. So, for example, a company called Strateos that we work with has a complete robotics laboratory. Instead of letting technicians stand there, it has robots and a small train track that can move throughout the room. Laboratory tests, so that, regardless of their geographic location, laboratory safety or time constraints, people trapped at home this year can continue the experiment.
LF: Obviously, making the world reduce carbon emissions is a huge priority. And, for the first time you have seen a company like United Airlines commit to its carbon footprint or zero carbon emissions. Opus 12 was graduated from two Ph.Ds and MBAs from Stanford University a few years ago. Their breakthrough is a catalyst material. For example, you can transport waste CO2 (hazardous substances) into the catalyst material and produce useful CO. For example, this year, they collaborated with Daimler to produce green polycarbonate auto parts. The material is exactly the same and can be easily inserted into existing products, but it is actually made by reusing carbon.The shift in consumer awareness of carbon materials is a huge opportunity.
LF: Yes, in the past we have seen many companies try to achieve green environmental protection by basically buying and trading carbon credits, and the transformation we are experiencing now is that everyone is saying: "Well, a degree, this is a bit of financial engineering. ; Now, we actually need to see these companies change their direct use of fossil fuels and their direct impact on carbon emissions.'[People are more and more aware that buying carbon offset transactions is not enough. Therefore, you are now Really see the promise of changing the process, the supply chain, and the final product once.
LF: From a therapeutic point of view, you tend to have a very clear script, the content of which is the potential exit method and who the acquirer is. We know that large pharmaceutical companies have ample cash and lack of assembly lines, so [these pharmaceutical giants] have to pick up available assets, and you will see them do this on a regular basis. And you have been successful, and you know what it looks like, so when placing a lot of bets on early treatments, it is clear that if there is a winner, you can be guaranteed.
The world of SPAC will become very interesting, because most of these companies do not rely on traditional business methods to operate, and it is not clear whether they operate as listed companies for a long time. Are they really buying?
[Another] The difference is that these companies will have such a huge amount of capital, but they will not be able to work hard in obscurity, so we all hope to find the traditional indicators of revenue in [listed companies], profits and those indicators, we will have to Looking at these SPACs and their growth from another angle, I am not sure about the public's acceptance of the market in the next 24 months. I think it is unclear whether we will do the calculations there.